Clinic
Methodist Hospitals of Dallas
Methodist Hospitals of Dallas was paid $13.18M by Medicaid between May 2019 and Dec 2024, across 154 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoMETHODIST HOSPITALS OF DALLAS
DALLAS, TX 75237
DALLAS, TX 75237
33aNPI1275592131assigned 03/20/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$13.18M
24GClaims386,694
24DCodes billed154
24AFirst – last monthMay 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#36 of 320
Median peer was paid$205K
This provider vs. median64×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 395 | $5K | |
| 2020 | 18,059 | $430K | |
| 2021 | 88,778 | $2.55M | |
| 2022 | 103,153 | $3.76M | |
| 2023 | 110,586 | $4.34M | |
| 2024incomplete | 65,723 | $2.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 16,799 | 15,353 | $3.58M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 31,967 | 29,833 | $2.61M |
| G0378 | Hospital observation service, per hour | 4.4% | 2,840 | 1,797 | $581K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.1% | 12,478 | 10,663 | $546K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 4,053 | 3,507 | $532K |
| 80053 | Comprehensive metabolic panel | 2.9% | 20,459 | 16,206 | $379K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 35,061 | 25,835 | $370K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 3,178 | 2,872 | $280K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 1,092 | 1,021 | $275K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 10,032 | 8,752 | $249K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 1,770 | 1,612 | $246K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 5,369 | 5,002 | $226K |
142 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 3,553 | $202K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 4,911 | $194K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 3,716 | $184K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.2% | 1,483 | $162K |
| 83880 | 1.1% | 5,090 | $144K | |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 2,299 | $143K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.1% | 1,709 | $142K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,105 | $106K |
| 81001 | <1% | 15,165 | $101K | |
| 84484 | <1% | 10,273 | $99K | |
| 84702 | <1% | 4,968 | $97K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,897 | $97K |
| 84703 | <1% | 14,343 | $95K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,637 | $88K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,399 | $78K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 359 | $67K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,517 | $67K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,673 | $58K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,673 | $58K |
| 83690 | <1% | 7,869 | $58K | |
| 80050 | General health panel | <1% | 475 | $57K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 686 | $55K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,450 | $50K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 967 | $37K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 454 | $34K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 446 | $33K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,798 | $31K |
| 84145 | <1% | 1,758 | $29K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 842 | $29K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 824 | $29K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 522 | $25K |
| 83735 | <1% | 4,775 | $24K | |
| 86850 | <1% | 1,502 | $23K | |
| 93976 | <1% | 267 | $23K | |
| 80143 | <1% | 1,200 | $22K | |
| 83605 | <1% | 2,492 | $21K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,831 | $21K |
| 80320 | <1% | 1,598 | $21K | |
| 80179 | <1% | 1,187 | $21K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,817 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 328 | $19K |
| 87040 | <1% | 2,801 | $19K | |
| 94644 | <1% | 445 | $19K | |
| 73562 | <1% | 562 | $19K | |
| 82550 | <1% | 3,072 | $18K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,459 | $17K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 165 | $16K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 846 | $16K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,503 | $15K |
| 85730 | <1% | 2,913 | $14K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 135 | $14K |
| 86769 | <1% | 445 | $13K | |
| 73030 | <1% | 464 | $13K | |
| 85610 | <1% | 3,553 | $12K | |
| 82803 | <1% | 507 | $10K | |
| 76801 | <1% | 117 | $10K | |
| 85379 | <1% | 1,285 | $10K | |
| 72100 | <1% | 222 | $8K | |
| 93971 | <1% | 60 | $8K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,704 | $8K |
| 97162 | <1% | 85 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,043 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,275 | $7K |
| 80069 | <1% | 1,604 | $7K | |
| 87081 | <1% | 908 | $7K | |
| 87210 | <1% | 1,168 | $6K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 18 | $6K |
| 87186 | <1% | 1,039 | $6K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 440 | $6K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 401 | $6K |
| 80061 | Lipid panel | <1% | 700 | $5K |
| 86900 | <1% | 2,270 | $5K | |
| 86901 | <1% | 2,267 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 43 | $5K |
| 82728 | <1% | 512 | $5K | |
| 80076 | <1% | 371 | $5K | |
| 72131 | <1% | 65 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,622 | $5K |
| 84100 | <1% | 1,737 | $5K | |
| 81003 | <1% | 2,474 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 401 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 253 | $4K |
| 73130 | <1% | 78 | $4K | |
| 83721 | <1% | 649 | $4K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 24 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,800 | $3K |
| 73630 | <1% | 143 | $3K | |
| 90715 | <1% | 188 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,667 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 17 | $2K |
| 86140 | <1% | 604 | $2K | |
| 87077 | <1% | 455 | $2K | |
| 83615 | <1% | 479 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 206 | $2K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,727 | $2K |
| 87088 | <1% | 297 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 951 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 59 | $2K |
| 73502 | <1% | 26 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 281 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 56 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 128 | $1K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 737 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,320 | $1K |
| 87807 | <1% | 57 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,619 | $836.11 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $823.05 |
| 87340 | <1% | 151 | $770.35 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 51 | $665.12 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 873 | $565.48 |
| 73610 | <1% | 13 | $559.76 | |
| 84132 | <1% | 128 | $519.27 | |
| 80329 | <1% | 60 | $488.52 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 183 | $425.82 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,108 | $415.15 |
| 90686 | <1% | 44 | $383.49 | |
| 72040 | <1% | 13 | $375.68 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 598 | $331.28 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 495 | $273.89 |
| 84439 | <1% | 60 | $250.69 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 265 | $222.75 |
| 85018 | <1% | 101 | $199.80 | |
| 74022 | <1% | 14 | $195.84 | |
| 82962 | <1% | 13,407 | $195.45 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 64 | $170.38 |
| 80164 | <1% | 28 | $157.62 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 19 | $145.70 |
| 36415 | Collection of venous blood by venipuncture | <1% | 194 | $140.84 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 9,880 | $136.33 |
| 94664 | <1% | 535 | $112.77 | |
| J3490 | Unclassified drugs | <1% | 1,371 | $103.71 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 230 | $78.70 |
| 96376 | <1% | 726 | $65.69 | |
| 0353U | <1% | 49 | $42.30 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 27 | $15.76 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 23 | $14.07 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 245 | $4.52 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 37 | $4.43 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 78 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 53 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 26 | $0.00 |
| C1769 | Guide wire | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBJERKE, CRAIG (EXECUTIVE VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Methodist Hospitals of Dallas | Dallas, TX | $12.59M |
| Methodist Hospitals of Dallas | Mansfield, TX | $3.20M |
| Methodist Hospitals of Dallas | Richardson, TX | $2.65M |
| Methodist Hospitals of Dallas | Midlothian, TX | $2.35M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.